CJH
VRTX icon

Christopher J. Hasenberg’s Vertex Pharmaceuticals VRTX Stock Holding History

Christopher J. Hasenberg’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		$10.2K Hold
23
– – ﹤0.01% 143
2025
Q1 		$11.1K Hold
23
– – ﹤0.01% 112
2024
Q4 		$9.26K Hold
23
– – ﹤0.01% 110
2024
Q3 		$10.6K Buy
+23
New +$11K ﹤0.01% 101

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Christopher J. Hasenberg's VRTX Position: Q2 2025 in Review

Christopher J. Hasenberg held its Vertex Pharmaceuticals (VRTX) position steady in Q2 2025 at 23 shares worth $10.2K. The position accounts for ﹤0.01% of the portfolio, ranked #143.

Christopher J. Hasenberg first reported a position in VRTX in Q3 2024 and has held it in 4 quarters since. The position peaked at $11.1K in Q1 2025. 1,559 funds tracked by Wall St. Rank hold VRTX as of Q2 2025.

  • Christopher J. Hasenberg held 23 shares of Vertex Pharmaceuticals worth $10.2K as of Q2 2025.
  • Christopher J. Hasenberg left its Vertex Pharmaceuticals share count unchanged in Q2 2025.
  • Vertex Pharmaceuticals made up ﹤0.01% of Christopher J. Hasenberg's portfolio in Q2 2025, its #143 holding.
  • Christopher J. Hasenberg first reported a position in Vertex Pharmaceuticals in Q3 2024 and has held it in 4 quarters since.
  • Christopher J. Hasenberg's Vertex Pharmaceuticals position peaked at $11.1K in Q1 2025.
  • 1,559 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2025.

Based on Christopher J. Hasenberg's 13F filing for Q2 2025, filed 9 Jul 2025.